<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01791894</url>
  </required_header>
  <id_info>
    <org_study_id>SKIN0015</org_study_id>
    <nct_id>NCT01791894</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma</brief_title>
  <acronym>ATO</acronym>
  <official_title>An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The V Foundation for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies arsenic trioxide in treating patients with basal cell
      carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to
      stop the growth of tumor cells, either by killing the cells or by stop them from dividing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine whether administration of arsenic trioxide (ATO) to patients with basal cell
      carcinoma is associated with a reduction in Gli messenger ribonucleic acid (mRNA) and protein
      levels in tumor biopsy samples, when compared to baseline levels.

      SECONDARY OBJECTIVES:

      I. To determine whether there is evidence of tumor size reduction of ATO against basal cell
      carcinoma in humans.

      OUTLINE:

      Patients receive arsenic trioxide intravenously (IV) over 2 hours on days 1-5. Courses repeat
      every 28 days in the absence of disease progression or unacceptable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Biomarker (GLI2 Protein) Levels</measure>
    <time_frame>baseline to day 33</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients With Stable Disease Post Treatment</measure>
    <time_frame>After 3 cycles of treatment (approx. 61 days)</time_frame>
    <description>Number of patients with stable disease post treatment by RECIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Progressive Disease Post Treatment by RECIST Criteria</measure>
    <time_frame>After 3 treatment cycles (approx. 61 days)</time_frame>
    <description>Patients with a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</measure>
    <time_frame>Baseline to cycle 3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Basal Cell Carcinoma of the Skin</condition>
  <condition>Recurrent Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (arsenic trioxide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (arsenic trioxide)</arm_group_label>
    <other_name>Arsenic (III) Oxide</other_name>
    <other_name>Arsenic Sesquioxide</other_name>
    <other_name>Arsenous Acid Anhydride</other_name>
    <other_name>AS2O3</other_name>
    <other_name>Trisenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with basal cell carcinoma (BCC)

          -  Patients ineligible for curative locoregional treatment and have either progressed on,
             did not tolerate, unwilling to try or ineligible for investigational smoothened
             antagonist such as vismodegib (GDC 0449), XL 139 (BMS 833923), IPI- 926, LDE225 and
             PF-04449913

          -  Life expectancy estimate &gt; 3 months

          -  Performance status Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 x institutional upper limit of normal

          -  Creatinine within normal institutional limits

          -  Corrected QT interval (QTC) by 12 lead electrocardiogram (EKG) &lt; 450 msecs

          -  Serum potassium within normal limits

          -  Magnesium within normal limits

          -  Calcium within normal limits

          -  Include the following: ability to understand and the willingness to sign a written
             informed consent document

          -  Patients must have evaluable tumor and be potentially eligible for pre and post ATO
             tumor biopsy

        Exclusion Criteria:

          -  Concurrent use of other Investigational agents is prohibited

          -  Patients with cardiac arrhythmias are excluded

          -  Patients receiving potassium wasting diuretics or amphotericin, while not excluded,
             must be noted to have theoretically increased arrhythmia risks with ATO

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, recurrent seizure history or psychiatric illness/social situations that
             would limit compliance with study requirements

          -  Pregnant women and breastfeeding women are excluded from this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Tang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2013</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <results_first_submitted>April 27, 2016</results_first_submitted>
  <results_first_submitted_qc>September 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2016</results_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jean Yuh Tang</investigator_full_name>
    <investigator_title>Associate Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic trioxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be submitted to scientific journal for publication and shared at scientific meetings</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We will recruit from medical clinic and other physicians who treat metastatic BCC</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IV ATO</title>
          <description>5 subjects will be treated with arsenic trioxide at 0.3 mg/kg daily via a 2 hour intravenous infusion for 5 days every 28 days (+/- 5 days) for a total of 3 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>5 patients with BCC who are not eligible for curative loco-regional treatment and have either progressed on, did not tolerate, unwilling to try or ineligible for investigational smoothened antagonist such as GDC 0449, XL 139 (BMS 833923), IPI- 926, LDE225 and PF-04449913 and fit the inclusion/exclusion criteria</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Arsenic Trioxide)</title>
          <description>arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Biomarker (GLI2 Protein) Levels</title>
        <time_frame>baseline to day 33</time_frame>
        <population>We recruited patients with biopsy-confirmed metastatic basal cell carcinoma who were had progressed on SMO inhibitors such as vismodegib (GDC 0449), IPI- 926, LEQ506 and LDE225.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Arsenic Trioxide)</title>
            <description>Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
arsenic trioxide: Given IV
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Biomarker (GLI2 Protein) Levels</title>
          <population>We recruited patients with biopsy-confirmed metastatic basal cell carcinoma who were had progressed on SMO inhibitors such as vismodegib (GDC 0449), IPI- 926, LEQ506 and LDE225.</population>
          <units>percentage decrease</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Stable Disease Post Treatment</title>
        <description>Number of patients with stable disease post treatment by RECIST criteria</description>
        <time_frame>After 3 cycles of treatment (approx. 61 days)</time_frame>
        <population>4 patients completed 3 cycles of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Arsenic Trioxide)</title>
            <description>Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
arsenic trioxide: Given IV
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Stable Disease Post Treatment</title>
          <description>Number of patients with stable disease post treatment by RECIST criteria</description>
          <population>4 patients completed 3 cycles of treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Progressive Disease Post Treatment by RECIST Criteria</title>
        <description>Patients with a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>After 3 treatment cycles (approx. 61 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV ATO</title>
            <description>5 subjects will be treated with arsenic trioxide at 0.3 mg/kg daily via a 2 hour intravenous infusion for 5 days every 28 days (+/- 5 days) for a total of 3 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Progressive Disease Post Treatment by RECIST Criteria</title>
          <description>Patients with a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</title>
        <time_frame>Baseline to cycle 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV ATO</title>
            <description>5 subjects will be treated with arsenic trioxide at 0.3 mg/kg daily via a 2 hour intravenous infusion for 5 days every 28 days (+/- 5 days) for a total of 3 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grade 3/4 Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</title>
          <units>number of occurrences</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Arsenic Trioxide)</title>
          <description>Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
arsenic trioxide: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE V3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>grade 3 infection</sub_title>
                <description>Patient had a grade 3 infection after the cycle 3 arsenic trioxide infusion. Patient recovered after hospital admission and IV antibiotic treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>grade 4 leukopenia</sub_title>
                <description>grade 4 leukopenia after the cycle 3 arsenic trioxide infusion. Patient recovered after hospital admission and IV antibiotic treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE V3</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>grade 1 asymptomatic atrial flutter</sub_title>
                <description>Patient 5discontinued treatment after the first cycle owing to grade 1 asymptomatic atrial flutter. He underwent repeated electrocardiography during a 1-week period, and the arrhythmia spontaneously resolved.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>transaminitis</sub_title>
                <description>grade 2 transaminitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean Y Tang MD PhD</name_or_title>
      <organization>Stanford University School of Medicine, Department of Dermatology</organization>
      <phone>650-721-7149</phone>
      <email>baileyhi@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

